CY1122521T1 - ΕΝΩΣΗ (6S,9AS)-N-BENZYΛO-6-((4-YΔPOΞYΦAINYΛO)ΜΕΘΥΛΟ)-4,7-ΔΙΟΞΟ-8-((6-(3-(ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΑΖΕΤΙΔΙΝΟ-1-ΥΛΟ)ΠΥΡΙΔΙΝ-2-ΥΛΟ)ΜΕΘΥΛΟ)-2-(ΠΡΟΠ-2-ΕΝ-1-ΥΛΟ)-OKTAΫΔPO-lH-ΠYPAZINO(2,l-C)(l,2,4)ΤΡΙΑΖΙΝΟ-1-ΚΑΡΒΟΞΑΜΙΔΙΟΥ - Google Patents
ΕΝΩΣΗ (6S,9AS)-N-BENZYΛO-6-((4-YΔPOΞYΦAINYΛO)ΜΕΘΥΛΟ)-4,7-ΔΙΟΞΟ-8-((6-(3-(ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΑΖΕΤΙΔΙΝΟ-1-ΥΛΟ)ΠΥΡΙΔΙΝ-2-ΥΛΟ)ΜΕΘΥΛΟ)-2-(ΠΡΟΠ-2-ΕΝ-1-ΥΛΟ)-OKTAΫΔPO-lH-ΠYPAZINO(2,l-C)(l,2,4)ΤΡΙΑΖΙΝΟ-1-ΚΑΡΒΟΞΑΜΙΔΙΟΥInfo
- Publication number
- CY1122521T1 CY1122521T1 CY20191100578T CY191100578T CY1122521T1 CY 1122521 T1 CY1122521 T1 CY 1122521T1 CY 20191100578 T CY20191100578 T CY 20191100578T CY 191100578 T CY191100578 T CY 191100578T CY 1122521 T1 CY1122521 T1 CY 1122521T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methyl
- ydpoxyphanylo
- pypazino
- octahydpo
- benzylo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- -1 PYRIDIN-2-YL Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013267687 | 2013-12-25 | ||
| PCT/JP2014/083932 WO2015098853A1 (ja) | 2013-12-25 | 2014-12-22 | （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122521T1 true CY1122521T1 (el) | 2021-01-27 |
Family
ID=53399298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100578T CY1122521T1 (el) | 2013-12-25 | 2019-05-31 | ΕΝΩΣΗ (6S,9AS)-N-BENZYΛO-6-((4-YΔPOΞYΦAINYΛO)ΜΕΘΥΛΟ)-4,7-ΔΙΟΞΟ-8-((6-(3-(ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΑΖΕΤΙΔΙΝΟ-1-ΥΛΟ)ΠΥΡΙΔΙΝ-2-ΥΛΟ)ΜΕΘΥΛΟ)-2-(ΠΡΟΠ-2-ΕΝ-1-ΥΛΟ)-OKTAΫΔPO-lH-ΠYPAZINO(2,l-C)(l,2,4)ΤΡΙΑΖΙΝΟ-1-ΚΑΡΒΟΞΑΜΙΔΙΟΥ |
Country Status (34)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| SG11201700855XA (en) | 2014-08-28 | 2017-03-30 | Eisai R&D Man Co Ltd | High-purity quinoline derivative and method for manufacturing same |
| BR112017017428A2 (pt) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | ?método para supressão do amargor de derivado de quinolina? |
| KR20250020678A (ko) | 2015-03-04 | 2025-02-11 | 머크 샤프 앤드 돔 엘엘씨 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| US11369623B2 (en) * | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| RU2723551C2 (ru) | 2015-06-23 | 2020-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида |
| RU2718048C2 (ru) | 2015-08-20 | 2020-03-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| AU2018219637B2 (en) | 2017-02-08 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| US20200197384A1 (en) | 2017-05-16 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| CA3155672A1 (en) | 2019-10-29 | 2021-05-06 | Yoichi Ozawa | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
| AR121544A1 (es) * | 2020-03-12 | 2022-06-15 | 3 2 Pharma | Inhibidores de la vía de señalización por cbp / catenina y sus usos |
| EP4238567A4 (en) | 2020-10-30 | 2024-09-04 | Keio University | NEW TREATMENT AND PREVENTION OF DISEASES RELATED TO SARCOPENIA |
| US20240352020A1 (en) * | 2021-08-26 | 2024-10-24 | 3+2 Pharma, Llc | Pyrazole-containing cbp/catenin antagonists and uses thereof |
| CN117794544A (zh) * | 2021-09-08 | 2024-03-29 | 卫材R&D管理有限公司 | 实体瘤治疗用医药组合物 |
| CN116262120A (zh) * | 2021-12-13 | 2023-06-16 | 上海中医药大学 | 特异性结合TRAF2的试剂在制备Wnt通路抑制剂中的应用 |
| WO2023140369A1 (en) * | 2022-01-18 | 2023-07-27 | Prism BioLab Co., Ltd. | Phosphoric acid derivatives |
| KR20240167633A (ko) | 2022-03-31 | 2024-11-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료용 약학 조성물 |
| CN115784934A (zh) * | 2022-11-22 | 2023-03-14 | 上海吉奉生物科技有限公司 | 一种酪氨酸衍生物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2310215T3 (es) * | 2001-10-12 | 2009-01-01 | Choongwae Pharma Corporation | Estructuras mimeticas de giro inverso y metodo relacionado. |
| US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| ES2552239T3 (es) | 2008-06-06 | 2015-11-26 | Prism Pharma Co., Ltd. | Miméticos de hélice alfa y métodos relacionados con los mismos |
| SG175045A1 (en) * | 2009-04-15 | 2011-11-28 | Jw Pharmaceutical Corp | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| KR101892575B1 (ko) * | 2010-10-14 | 2018-08-31 | 제이더블유중외제약 주식회사 | 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 |
| WO2012115286A1 (en) * | 2011-02-25 | 2012-08-30 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
-
2014
- 2014-12-19 US US14/577,660 patent/US9174998B2/en active Active
- 2014-12-21 JO JOP/2014/0373A patent/JO3809B1/ar active
- 2014-12-22 BR BR112016013572-5A patent/BR112016013572B1/pt active IP Right Grant
- 2014-12-22 DK DK14873998.0T patent/DK3088401T3/da active
- 2014-12-22 UA UAA201606261A patent/UA116923C2/uk unknown
- 2014-12-22 MY MYPI2016702025A patent/MY173946A/en unknown
- 2014-12-22 MX MX2016007705A patent/MX365376B/es active IP Right Grant
- 2014-12-22 RU RU2016122867A patent/RU2669805C2/ru active
- 2014-12-22 TW TW103144928A patent/TWI681961B/zh active
- 2014-12-22 EP EP14873998.0A patent/EP3088401B1/en active Active
- 2014-12-22 AU AU2014371148A patent/AU2014371148B2/en active Active
- 2014-12-22 AR ARP140104850A patent/AR098908A1/es active IP Right Grant
- 2014-12-22 HR HRP20190908TT patent/HRP20190908T1/hr unknown
- 2014-12-22 RS RS20190665A patent/RS58955B1/sr unknown
- 2014-12-22 KR KR1020167015608A patent/KR102307053B1/ko active Active
- 2014-12-22 JP JP2015554886A patent/JP6085040B2/ja active Active
- 2014-12-22 SG SG11201604496YA patent/SG11201604496YA/en unknown
- 2014-12-22 CN CN201480067017.7A patent/CN105873932B/zh active Active
- 2014-12-22 ES ES14873998T patent/ES2728353T3/es active Active
- 2014-12-22 LT LTEP14873998.0T patent/LT3088401T/lt unknown
- 2014-12-22 SI SI201431226T patent/SI3088401T1/sl unknown
- 2014-12-22 PE PE2016000711A patent/PE20160932A1/es unknown
- 2014-12-22 PL PL14873998T patent/PL3088401T3/pl unknown
- 2014-12-22 HU HUE14873998 patent/HUE044541T2/hu unknown
- 2014-12-22 PT PT14873998T patent/PT3088401T/pt unknown
- 2014-12-22 WO PCT/JP2014/083932 patent/WO2015098853A1/ja active Application Filing
- 2014-12-22 CA CA2932435A patent/CA2932435C/en active Active
- 2014-12-22 TR TR2019/08392T patent/TR201908392T4/tr unknown
- 2014-12-22 ME MEP-2019-158A patent/ME03391B/me unknown
- 2014-12-22 SM SM20190306T patent/SMT201900306T1/it unknown
-
2016
- 2016-06-01 IL IL245961A patent/IL245961A0/en active IP Right Grant
- 2016-06-07 PH PH12016501079A patent/PH12016501079A1/en unknown
- 2016-06-09 CL CL2016001419A patent/CL2016001419A1/es unknown
-
2019
- 2019-05-31 CY CY20191100578T patent/CY1122521T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122521T1 (el) | ΕΝΩΣΗ (6S,9AS)-N-BENZYΛO-6-((4-YΔPOΞYΦAINYΛO)ΜΕΘΥΛΟ)-4,7-ΔΙΟΞΟ-8-((6-(3-(ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΑΖΕΤΙΔΙΝΟ-1-ΥΛΟ)ΠΥΡΙΔΙΝ-2-ΥΛΟ)ΜΕΘΥΛΟ)-2-(ΠΡΟΠ-2-ΕΝ-1-ΥΛΟ)-OKTAΫΔPO-lH-ΠYPAZINO(2,l-C)(l,2,4)ΤΡΙΑΖΙΝΟ-1-ΚΑΡΒΟΞΑΜΙΔΙΟΥ | |
| CY1125586T1 (el) | Παραγωγα κινολινης για τη θεραπευτικη αντιμετωπιση φλεγμονωδων ασθενειων | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| PH12014502788A1 (en) | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | |
| CY1121792T1 (el) | Ετεροκυκλικη ενωση | |
| CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
| CY1121901T1 (el) | Ενωσεις τριαζολοπυριμιδινης και χρησεις αυτων | |
| CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
| CY1118739T1 (el) | Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch | |
| CY1120474T1 (el) | Χημικες ενωσεις | |
| CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
| CU24517B1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CY1123988T1 (el) | Ενωση πυριδινης | |
| CY1117097T1 (el) | Ενωσεις ετεροαρυλο πυριδονης και αζα-πυριδονης ως αναστολεις της δρασης της βτκ | |
| CY1117905T1 (el) | Αναστολεις πρωτεϊνικης κινασης | |
| CY1117809T1 (el) | Ορισμενες αμινο-πυριμιδινες, συνθεσεις αυτων, και μεθοδοι για χρηση αυτων | |
| UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
| EA201401054A1 (ru) | N-циклиламиды в качестве нематоцидов | |
| CY1117105T1 (el) | Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao | |
| AR097158A1 (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| MX2015001720A (es) | Hetero-azepinonas sustituidas. | |
| CY1117843T1 (el) | Νεα παραγωγα θειενοπυριμιδινης, διεργασιες για την παρασκευη αυτων και θεραπευτικες χρησεις αυτων | |
| MA40171A (fr) | Dérivés d'azamophinan et leur utilisation | |
| CY1119425T1 (el) | Ενωσεις φαινοξυαιθυλο πιπεριδινης | |
| CY1119583T1 (el) | Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα |